EFEMP1 and glioblastoma: Anti-adhesion has evolved to a promising therapeutic concept in oncology [64], and recently, an “anti-ECM” strategy using a function-blocking antibody against Fibulin 3 has been proved in treatment of murine glioblastoma [65].